In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment right up until sickness progression or maybe the contributors are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit merchandise within three times https://abbv-744-and-its-impact-o91368.smblogsites.com/32027932/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options